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Abstract. Background: Carboplatin and paclitaxel form the
cornerstone of chemotherapy for epithelial ovarian cancer,
however, drug resistance to these agents continues to present
challenges. Despite extensive research, the mechanisms
underlying this resistance remain unclear. Materials and
Methods: A 2D-gel proteomics method was used to analyze
protein expression levels of three human ovarian cancer cell
lines and five biopsy samples. Representative proteins
identified were validated via western immunoblotting.
Ingenuity pathway analysis revealed metabolomic pathway
changes. Results: A total of 189 proteins were identified with
restricted criteria. Combined treatment targeting the
proteasome-ubiquitin pathway resulted in re-sensitisation of
drug-resistant cells. In addition, examination of five surgical
biopsies of ovarian tissues revealed α-enolase (ENOA),
elongation factor Tu, mitochondrial (EFTU), glyceraldehyde-
3-phosphate dehydrogenase (G3P), stress-70 protein,
mitochondrial (GRP75), apolipoprotein A-1 (APOA1),
peroxiredoxin (PRDX2) and annexin A (ANXA) as candidate
biomarkers of drug-resistant disease. Conclusion: Proteomics
combined with pathway analysis provided information for an
effective combined treatment approach overcoming drug
resistance. Analysis of cell lines and tissues revealed potential
prognostic biomarkers for ovarian cancer. 
Epithelial ovarian cancer (EOC) is the second commonest
cause of death from gynaecological cancer worldwide, with
approximately 239,000 new cases diagnosed worldwide and
142,000 deaths annually as a result of its late presentation (1).
Standard treatment for advanced EOC (stage 3 and 4) includes
surgery and chemotherapy. Results of clinical trials performed
over the past 30 years have identified the platinum drugs
(carboplatin or cisplatin) and taxanes (paclitaxel/Taxol™ or
docetaxel/Taxotere™) given intravenously as the best standard
first-line treatments (2-6).
As in other types of cancer, the effectiveness of the
aforementioned chemotherapeutic agents is limited by drug
resistance. The acquisition of resistance constitutes a serious
impediment to improving outcomes in oncology, such as
disease-free survival (DFS) and overall survival (OS).
Typically, many patients with advanced EOC show an
excellent response (70-80%) during their primary treatment.
However, this is frequently followed by the development of
fatal drug resistance, with DFS as early as 6 months
following completion of their primary treatment (7, 8). This
is reflected in the poor 5-year overall survival of patients with
advanced ovarian cancer, which ranges between 25-35%.
Although the molecular basis for platinum resistance
remains largely undefined, it is considered multi-factorial
and numerous mechanisms seem to be involved. Many drug-
resistant cancer cells exhibit pleomorphic phenotypes, the
result of multiple altered pathways involving reduced drug
uptake, faulty DNA-damage recognition and repair, and an
inappropriately reduced apoptotic response (9). Drug
resistance may either occur through insufficient DNA
binding, which is limited by reduced accumulation of the
drug, enhanced drug efflux and cisplatin inactivation by
coordination to sulphur-containing proteins (10), or mediated
after DNA-binding via increased repair of platinum–DNA
adducts (10, 11), increased tolerance to platinum-induced
DNA damage (12), or through decreased expression or loss
of apoptotic signaling pathways (9).
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Approaches to overcoming taxane resistance include the
use of multidrug resistance modulators (13), if the resistance
correlates with p-glycoprotein (P-gp) overexpression, or
novel cytotoxic molecules, developed on the basis of activity
in Taxol-resistant models, such as the epothilones (14),
although these approaches have had limited success in
clinical trials (15).
Proteomics has been very useful in the analysis of
complex proteomic samples as the identification of
individual protein scans facilitates and enhances our
understanding of molecular cell biology.
A small number of in vitro proteomic studies have been
carried out which compare the drug-resistance profile of
ovarian cancer cell lines with their sensitive counterparts.
For example, ovarian cancer cell line IGROV1 and its
cisplatin-resistant counterpart IGROV1-R10 (16); SKOV3
and A2780 with four drug platinum-resistant (17, 18);
SKOV3 and A2780 and their derived counterparts with
acquired resistance to antimitotic agents and microtubule
inhibitors (19-21).
In the present study, a proteomics approach was used to
identify markers of drug-resistant ovarian cancer. Protein
samples extracted from cancer cell lines and tumour biopsies
were subjected to two-dimensional gel electrophoresis (2D-GE)
techniques, followed by in-gel trypsin digestion and liquid
chromatography-tandem mass spectrometry (LC-MS/MS). The
differential protein expression levels were assessed using
pathway analysis and representative proteins were selected for
validation using western blotting. Following the identification
of particular pathway alterations, we employed the approach
of using the specific pathway inhibitor bortezomib to reverse
drug resistance in drug-resistant cell lines with increased
proteasome activity. Identification of selected proteins from
biopsy samples were also compared with cell line samples,
which revealed potential cancer biomarkers. 
Materials and Methods
Materials. Urea, 1,4-dithiothreitol (DTT), triton X-100, glycerol,
bromophenol blue, iodoacetamide, agarose, acetic acid, sodium
dodecyl sulphate (SDS), Tris, carboplatin, paclitaxel and 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
dye were purchased from Sigma-Aldrich, Dorset, UK. 3-[(3-
Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS),
methanol, ethanol, formic acid, water, hydrochloric acid and
acetonitrile were from Fisher Scientific, Loughborough, UK. Thiourea,
ampholyte solution and ammonium bicarbonate were obtained from
Fluka, Dorset, UK. All solvents used for mass spectrometry analysis
were high-pressure liquid chromatography (HPLC) grade.
The parental ovarian cancer cell line model PEO1 was used as a
drug-sensitive reference cell line. Novel drug-resistant models,
derived from the parental line, were used alongside their respective
drug-sensitive parental counterparts. 
The ovarian tissues (SOV-1, SOV-2, SOV-3, SOV-4, SOV-5)
were obtained by surgical biopsy from five different patients, four
of whom were diagnosed with ovarian cancer and one with
endometriosis, a benign gynaecological condition. Relevant clinical
information regarding tissue histology, stage of disease and response
to chemotherapy are summarised in Table I.
Cell culture. The PEO1 cell line (originally obtained from Professor F.
Balkwill, formerly ICRF, London, UK) was cultured as monolayers in
RPMI-1640 medium and supplemented with 10% heat-inactivated foetal
calf serum (FCS; Invitrogen, Paisley, UK). Drug-resistant variants were
derived by step-wise incubation of the inducing agent over a number of
months until a stable resistance phenotype was acquired. This resulted
in the paclitaxel-resistant PEO1TaxR variant line (maintenance dose 8
nM paclitaxel) with approximately 15-fold resistance to paclitaxel, and
carboplatin-resistant PEO1CarboR variant line (maintenance dose 2 μM
carboplatin) with approximately 8-fold resistance to carboplatin (22).
Cell confluence was checked using a light microscope before harvesting.
Cells were harvested by trypsinization with 0.05% Trypsin-EDTA
solution (Gibco, Invitrogen, UK), collected into 1.5 ml microfuge tubes
and centrifuged at 11,337 × g for 10 min at room temperature in a
Technico Maxi centrifuge (Fisher Scientific, Loughborough, UK). The
supernatant was discarded and the pellets were washed three times with
phosphate-buffered saline (PBS) (Oxoid, Loughborough UK), before
being stored at −80˚C until further use.
Protein extraction from cells. For the tissue biopsies used in this
study, patients gave their informed consent prior to surgery in
accordance with the National Ethics Committee REC (application
number 07/Q11909/14). Tumour biopsies were collected and snap-
frozen during surgery (either primary laparotomy or interval
debulking following chemotherapy). The histological assessment of
the remaining tumour was undertaken by a specialist gynaecological
pathologist (Section of Histopathology, Royal Surrey County
Hospital, Guildford, Surrey, UK) and discussed as part of routine
patient care at the weekly multidisciplinary team meeting. 
Dry-stored tissue or cell line-derived pellets were thawed and
resuspended in 200 μl lysis buffer (50 mMTris-HCl, pH 8.3; 0.5%
SDS) containing protease inhibitor cocktail (Amersham Biosciences,
Little Chalfont, UK). The cellular mixtures were boiled for 10 min
at 100˚C and spun at 11,337 × g for 30 min at 4˚C in a Biofuge
Fresco centrifuge (Heraeus, Northbrook, UK). The supernatants
with dissolved proteins were transferred to clean microfuge tubes
and stored at −80˚C until further use. 
Protein extraction from tissues. Ovarian tissues were individually
weighed and washed with 40 mM Tris-HCl, pH 8 to remove excess
blood. Tissue samples were cut into 2-5 mm pieces, which were then
placed into microfuge tubes on ice and a suitable volume of modified
lysis buffer (9.5 M urea, 4% CHAPS, 0.1% Triton X-100, 5 mM
DTT) containing protease inhibitor cocktail (Amersham Biosciences)
was added to each tube. Tissues were homogenised using steel beads
in a TissueLyser (Qiagen, Manchester, UK) twice for 2 min at a
frequency of 30.0 cycles/s. After homogenisation, tissue lysates were
transferred to clean tubes followed by centrifugation to remove
cellular debris at 11,337 × g for 30 min at 4˚C in a Biofuge Fresco
centrifuge (Heraeus). The supernatants were carefully transferred to
other tubes and stored at −80˚C until further use.
Protein concentration assay. Protein concentrations of all cell and
tissue lysate samples were determined using the RCDC Protein Assay
Kit (Bio-Rad, Hemel Hempstead, UK). Bovine plasma γ-globulin
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(Bio-Rad) was used as protein standard and serial dilutions were
prepared from the initial stock concentration of 1.5 mg/ml, using the
same buffer as for the samples and used to prepare a standard curve.
The assay was performed in triplicate and in accordance with the
manufacturer’s instructions. Absorbance values were measured at 
750 nm and linear regression and protein concentrations calculated.
Two-dimensional gel electrophoresis. First dimension and
isoelectric focusing: Cell and tissue lysates, with 50 μg protein,
were pre-treated with ReadyPrep 2-D Clean Up Kit (Bio-Rad) to
remove contaminants. Isoelectric focusing was performed using
Protean IEF Cell (Bio-Rad) with 11 cm ReadyStrips, pH 3-10 non-
linear (Bio-Rad). Pellets resulting from the pre-treatment were
resuspended in rehydration buffer (7 M urea, 2 M thiourea, 4%
CHAPS, 20 mM DTT, 0.5% ampholyte solution pH 3-10) to a total
volume of 200 μl. Mixtures were centrifuged at 13,148 × g for 
5 min at room temperature and the supernatants were loaded into a
focusing tray. The immobilised pH gradient (IPG) strips were placed
above the mixtures and the liquid was allowed to distribute for 1 h
before covering the strips with mineral oil (Bio-Rad). The
rehydration procedure was performed at 50 V (active rehydration)
for 12 h. The focusing was then started and carried out on a rapid
ramp according to the following steps: 250 V for 15 min; 8,000 V
for 2 h; 8,000 V until 40,000 V/h. Both rehydration and focusing
procedures took place at 20˚C. IPG strips were immediately used
for the second dimension or stored at −80˚C.
Reduction and alkylation: IPG strips were washed three times
with equilibration buffer (0.375 M Tris-HCl pH 8.8, 6 M urea, 20%
glycerol, 2% SDS) and then incubated in 55 mM DTT solution in
equilibration buffer for 1 h at room temperature with constant
shaking. After incubation, the DTT solution was discarded and 
100 mM iodoacetamide solution in equilibration buffer was added
to the strips. The strips were then incubated in the dark for 1.5 h at
room temperature with constant shaking, after which the
iodoacetamide solution was discarded. The alkylation process was
stopped by washing the strips with an equal volume of rehydration
buffer without DTT (7 M urea, 2 M thiourea, 4% CHAPS) for 
10 min at room temperature.
Second dimension–sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE): Each strip was transferred to the top
of a Criterion TGX Precast Gel, any kD, IPG + 1 well comb, 11 cm
IPG strip (Bio-Rad). A molecular weight marker was loaded into the
single well. The IPG strips were fixed to the second dimension gels
with 1% low melting agarose in stacking buffer (0.5 M Tris-HCl pH
6.8) with a trace of bromophenol blue. After allowing the agarose
to solidify for 5 min and filling the reservoirs with 1x Tris-Glycine-
SDS running buffer (Bio-Rad), electrophoresis was started. This
process was carried out using a Criterion Cell System (Bio-Rad) at
150 V until the dye front had reached the bottom of the gel. Gels
were stained immediately after the second dimension.
Staining and image analysis: Gels were silver stained using a
Pierce Silver Stain Kit (Thermo Scientific, London, UK) according
to the manufacturer’s instructions. Spots of interest were selected
either visually or using PDQuest Advanced software version 8.0.1
(Bio-Rad). Protein expression levels were calculated as fold
regulation, i.e. comparing parent PEO1 cells vs. control (drug-
resistant variant). An arbitrary number of 1,000 was set for
exclusive spots, e.g. "-1,000" means only found in control and
"1,000" indicates only found in sample (See Supplementary data).
In-gel trypsin digestion. Spots of interest were cut into 1-2 mm3
gel pieces, either manually or using an EXQuest Spot Cutter (Bio-
Rad), which were placed into 0.6 ml siliconized tubes and rinsed
twice with 190 μl of wash solution (50% methanol + 5% acetic
acid) at room temperature for 3 h and overnight, respectively. Gel
pieces were then dehydrated in 190 μl of acetonitrile at room
temperature for 5 min, after which the samples were dried in a
vacuum centrifuge for 3 min. Sample reduction was performed
with 30 μl of 10 mM DTT in 100 mM ammonium bicarbonate
solution at room temperature for 30 min, followed by alkylation
with the same volume of 100 mM iodoacetamide in 100 mM
ammonium bicarbonate solution at room temperature for another
30 min. Samples were dehydrated again in 190 μl of acetonitrile at
room temperature for 5 min and dried in a vacuum centrifuge for
3 min. Gel pieces were rehydrated in 190 μl of 100 mM
ammonium bicarbonate at room temperature for 10 min and then
dehydrated in acetonitrile and dried in a vacuum centrifuge.
Finally, samples were rehydrated on ice for 10 min with 20 μl of
trypsin solution [20 ng/μl sequencing-grade modified porcine
trypsin (Promega, Southampton, UK) in ice-cold 50 mM
ammonium bicarbonate pH 8.0] with occasional vortex mixing.
Samples were spun down for 30 s and excess trypsin solution was
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Table I. Clinical information from five different patients and their respective ovarian tissue biopsies.
Sample                    Histology               Stage of                   Pre- or Post-                            Response to                    Survival                      Notes
                                                               disease                    chemotherapy                          chemotherapy                      time
SOV-1                 Endometriosis               N/A                              N/A                                          N/A                       Alive & well           Non-malignant 
                                                                                                                                                                                                                           condition
SOV-2                       Serous                     IVa           Previously treated – interval              No response,                38 months†                        -
                          adenocarcinoma                                       debulking sample                  progressive disease
SOV-3                       Serous                     IIIc           No previous chemotherapy,          Complete response            >60 months                        -
                          adenocarcinoma                                        primary surgery                                                             (alive & well)
SOV-4                     Clear cell                  IVa           No previous chemotherapy,            Partial response               34 months†                        -
                          adenocarcinoma                                        primary surgery
SOV-5                       Serous                     IIb            No previous chemotherapy,            Partial response              106 months†           BRCA1 mutant
                          adenocarcinoma                                        primary surgery
BRCA1: Breast Cancer 1. †Denotes death; Pre- or Post-chemotherapy: drug therapy timing in relation to sample taken; N/A: not applicable.
removed. An aliquot of 10 μl of 50 mM ammonium bicarbonate
solution was added to prevent gel pieces from drying and proteins
were digested overnight at 37˚C.
After digestion, 30 μl of 50 mM ammonium bicarbonate solution
were added to each tube containing the gel pieces and the mixtures
were vortexed for 10 min, after which supernatants were collected
and transferred to new tubes. Peptides were firstly extracted from
the gel pieces with 30 μl of extraction buffer I (50% acetonitrile +
45% water + 5% formic acid) for 10 min. A second extraction was
performed with 30 μl of extraction buffer II (85% acetonitrile +
10% water + 5% formic acid) for another 10 min. Supernatants were
collected after each extraction and combined with the previous
fraction. The extracts volume was reduced to <10 μl by evaporation
in a vacuum centrifuge. The final dried extracts were re-dissolved
in 99.9% water + 0.1% formic acid, sonicated for 10 min,
centrifuged for 5 min and transferred to MS vials. 
LC-MS/MS analysis. Peptides were analyzed on a Waters CapLC system
coupled to the front end of a Waters Micromass Q-ToF Premier (Waters
Micromass, Manchester, UK). Depending on the intensity of the spot on
the 2-D gel, 1-5 μl were injected per sample. A 63-min gradient LC
method was followed: t=0.1 min, 5% mobile phase B; t=3 min, 5% B;
t=40 min, 28% B; t=49 min, 80% B; t=52min, 80% B; t=53 min, 5% B
and t=63 min, 5% B (mobile phase A: 5% Acetonitrile (ACN) + 0.1%
formic acid; B: 95% ACN + 0.1% formic and). Initial flow from the
CapLC was at 6 μl/min, which was split prior to the column such that
the flow through the column to the MS was only 200 nl/min. Peptides
eluted off the column were directly sprayed into the MS for analysis.
The acquisition and processing software used was Waters MassLynx
Version 4.1. MS was monitored over a m/z range of 400-1700 Da and
MS/MS was monitored over a m/z range of 50-1700 Da. Capillary was
at 1.8 kV, cone voltage at 35 V and collision energy at 35 eV.
Data processing and database searching. Raw LC-MS/MS data were
processed and .pkl files created using MassLynx Version 4.1 (Waters)
and used to perform database searches using the online search engines
Mascot (version 2.4; Matrix Science, Boston, MA, USA) and X!Tandem
(The GPM, version 2012/10/19, http://www.thegpm.org/index.html), and
choosing SwissProt databases (last used v2012/11, number of entries
538,585) to look for human proteins (taxonomy: Homo sapiens).
Searches were performed without restriction of protein molecular mass
or pI, but with variable modifications such as carbamidomethylation of
cysteines and oxidation of methionine residues. One trypsin miscleavage
was allowed. Peptide and fragment mass tolerances were set to ±0.1 Da
and peptide charge to 2+, 3+ and 4+. Instrument type chosen was ESI-
QUAD-TOF. 
Scaffold 3 software version 3.6.4 (Proteome Software, OR, USA)
was used to combine and compare proteins identified among
different biological samples and to group proteins by biological
relevance and molecular function.
Pathway analysis. Pathway analysis was performed using
Ingenuity Pathway Analysis (IPA) software (Ingenuity Systems,
Qiagen, CA, USA).
Western blot. A total of 20 μg of protein per well was loaded onto
Bio-Rad precastMini-Protean TGX precast gels, any kD, 10-well
comb, 30 μl/well (Bio-Rad). Proteins were separated by SDS-PAGE
and transferred onto nitrocellulose membranes (Hybond-C Extra;
Amersham Biosciences) using a Mini Trans-Blot Transfer Cell (Bio-
Rad) for 1 h at 100 V.
After blocking with 1% bovine serum album (Sigma-Aldrich) or
1 % milk (dried skimmed milk, Marvel) in TBS buffer for 1 h at
room temperature, the membranes were probed with rabbit
polyclonal primary antibodies, diluted in blocking solution,
overnight at 4˚C. Antibodies to 14-3-3, anti-thioredoxin (TRX) and
ubiquitin-conjugating enzyme 2 K (UBE2K) were diluted at 1:1000.
Antibodies to ubiquintin-conjugating enzyme E2 variant 2 (MMS2)
and actin were diluted at 1:100. Antibody to phosphoglycerate
mutase 1 (PGAM1) was diluted at 1:100. A list of the primary
antibodies used, their supplier and respective product code is shown
in the Supplementary data.
The membranes were then washed 4x with TBS buffer containing
0.05% Tween 20 (Sigma-Aldrich) and subsequently incubated for 1.5
h at room temperature with a horseradish peroxidase (HRP)-
conjugated donkey anti-rabbit secondary antibody (ab16284, Abcam,
UK) at a dilution of 1:2,000, in the same blocking solution as the
primary antibody. After incubation with secondary antibody,
membranes were washed again with TBS buffer containing 0.05%
Tween 20. Protein bands were developed using a SuperSignal West
Pico Chemiluminescent Substrate (Thermo Scientific) and visualised
with a Bio-Rad gel imager using Image Lab software (Bio-Rad). The
western blot assay was performed at least twice for each antibody.
Cytotoxicity testing using cell viability. MTT dye (Sigma) was
dissolved in sterile PBS at a concentration of 5 mg/ml; For the MTT
assay, single-cell suspensions (PEO1, PEO1CarboR and
PEO1TaxR) were seeded into a 96-well plate at a density of 0.6×104
per well. Cells were allowed to grow and attach under standard
culture conditions for 24 h at 37˚C with 5% CO2. The next day,
serial dilutions of bortezomib (Selleck Chemicals, Houston, TX,
USA) in medium were prepared and appropriate aliquots added to
the wells. Cells were incubated with the drugs for 72 h. To evaluate
cell viability, 20 μl MTT dye (5 mg/ml in PBS) was added to each
well. After an incubation period of 4 h at 37˚C, the medium was
carefully aspirated from the wells and 200 μl dimethyl sulfoxide
was added. The plates were then subjected to gentle agitation to
suspend the formazan crystals and the purple colour was detected
at 540 nm using a plate reading spectrophotometer (Labsystems
Multiskan RC Plate Reader; Thermo Scientific). Dose-responses
were created in GraphPad (La Jolla, CA, USA) and the half
maximal-inhibitory concentration (IC50) values calculated by fitting
with the 4-parameter model (Table II). 
Assessment of apoptotic response following drug treatment. Ovarian
cancer cells were seeded into 25 cm2 flasks at approximately 40%
confluence. After attachment, the cells were then treated with carboplatin
(5 μM), bortezomib (50 nM) singly and in combination for 48 h. Cells
were then harvested (including the floating and attached populations
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Table II. Data obtained using the MTT assay in human ovarian cancer
cell lines treated with bortezomib.
Cell line                                                                 IC50 Bortezomib (μM)
PEO1 (parental )                                                              15.8 (3.9)
PEO1CarbR (carboplatin-resistant)                              41.1 (15.5)#
PEO1TaxR (paclitaxel-resistant)                                 152.4 (24.6)*
Significantly different from IC50 for PEO1 at #p=0.05, *p=0.008.
combined in the drug-treated cells) and subjected to Annexin V assay
combining with propidium iodide according to The manufacturer’s
instructions (CN Biosciences, Beeston, UK). Samples were then
subjected to flow cytometry using FL1 for fluorescein Isothiocyanate
(FITC)-conjugated annexin and FL3 for propidium iodide on a Coulter
EPICS flow cytometer (Beckman Coulter, Brea, CA, USA). Each
sample was assessed using collection of 10,000 events.
Results
Protein identification. Protein extract solutions from the PEO1
parental (drug-sensitive), PEO1TaxR, and PEO1CarbR cell lines
were analyzed by 2D-GE (see Supplementary data) according to
the procedure reported elsewhere (23) with some slight
modifications. Duplicates had been run to confirm
reproducibility. Two replicates were taken for protein analysis
after reproducible gels had been obtained. One replicate was
overstained deliberately in order to visualize spots of weakly
expressed proteins; another replicate was slightly understained.
Only those spots that were either exclusively present, or two-fold
higher (assessed by PDQuest Advanced 8.0.1) were selected for
excision and further analysis by LC-MS/MS (typically twice, see
Supplementary data). In this research, a total of 189 proteins
were identified using restricted criteria (Table III). 
Target validation. Western blotting was used to validate
protein targets of interest in ovarian cancer cell lines (Table
IV). Six proteins from different pathways were investigated:
glycolysis I and gluconeogenesis I pathways (PGAM1) (24),
ubiquitin-conjugating enzyme E2 variant 2 (UB2V2) and
UBE2K (ubiquitination pathway) (24), 14-3-3 protein (14-3-
3 signalling pathway) and thioredoxin (THIO) [nuclear factor
erythroid 2-related factor 2 (NRF2)-mediated oxidative stress
response pathway] (24, 25).
Pathway analysis. Pathway analysis was performed with the
Ingenuity Pathway Analysis (IPA) software and the fold
regulation data (see Supplementary data). In IPA, relationships
between molecules are represented by canonical pathways,
which display the molecules of interest within well-established
signalling or metabolic pathways. Each relationship between
molecules was created using scientific information contained
in the Ingenuity Knowledge Base and molecules of interest are
related to known biological functions and disease states (26).
Preliminary observations indicated that the main pathways
were common to both quantification approaches used for the
analysis. The top 10 influenced pathways were Glycolysis I,
Gluconeogenesis I, Protein Ubiquitination Pathway,
Remodelling of Epithelial Adherens Junctions (important in the
epithelial–mesenchymal transition pathway and cell adhesion),
14-3-3-Mediated Signalling, NRF2-mediated Oxidative Stress
Response, Aspartate Degradation II, Aldosterone Signalling in
Epithelial Cells, TCA Cycle II (Eukaryotic) and Guanine and
Guanosine Salvage I (Figure 1).
Investigation of pathway-targeted combined treatment of the
protein ubiquitination pathway. Assessment of bortezomib
sensitivity in human ovarian cancer cell lines: As shown in
Table II, the bortezomib sensitivity of the panel of cell lines
used in this study varied significantly, indicated by the IC50
values obtained.This part of the study was designed to guide
us as to the dose of bortezomib to use in the apoptosis
experiments. Clearly, the carboplatin-resistant and paclitaxel-
resistant variants of PEO1 appeared to be relatively resistant
to bortezomib, particularly the PEO1TaxR subline.
Combinations of bortezomib with either paclitaxel or
carboplatin show synergistic effects in drug-resistant ovarian
cancer cells. Figure 2 shows the effect of carboplatin, and
paclitaxel in combination with bortezomib in sensitive and
resistant PEO1 cell lines. The extent of apoptosis seen for
carboplatin treatment alone was as expected, with the
parental (drug-sensitive) cell line exhibiting significantly
more apoptosis than that seen for the carboplatin-resistant
line (p=0.0001, Figure 2A). However, the extent of apoptosis
seen for PEO1 and PEO1CarbR treated with bortezomib was
not significantly different at the 48 h time window used in
these experiments. The most important finding of these
experiments was the extent of apoptosis seen for the drug-
resistant PEO1CarbR cells treated with the drug
combination, which exceeded that seen for the PEO1
parental line. If the apoptotic effects of the individual drugs
(bortezomib and carboplatin) were added and then compared
with the same for the combination treatment (i.e.
simultaneous drug treatment) then a paired t-test analysis
gave a highly significant p-value (0.006).
In addition, we can see the relative resistance of the
PEO1TaxR cells to both paclitaxel and to bortezomib, at the
doses used (Figure 2B). However, the effect of the
combination treatment on the PEO1TaxR cells was
significant (p<0.005) compared to the effect seen for the
parental PEO1 cells (p>0.5), (taking into account the effects
of the individual drug treatment on the apoptotic readout).
Analysis of clinical biopsies of ovarian cancer for protein
markers of disease status. We carried out a limited pilot
study comprising of five clinical biopsies of human ovarian
tissue (SOV-1/2/3/4/5, Table I). These tissue samples were
analyzed by 2D-GE (See Supplementary data) and spots
were selected (See Supplementary data) according to the
following criteria: i) exclusive presence in only one gel, ii)
2-fold and iii) 5-fold change in intensity. Spots were cut and
analysed by MS and identifications were obtained using the
same restricted criteria (Table III).The results confirmed that
a number un-regulated proteins in the clinical samples were
involved in the glycolysis I and gluconeogenesis I pathways,
validating previous reports describing chemoresistant cancer
with elevated aerobic glycolysis (27).
Cruz et al: Identification of Drug Resistance-associated Proteins in Ovarian Cancer
39
CANCER GENOMICS & PROTEOMICS 14: 35-52 (2017)
40
Table III. Proteins identified in the ovarian cancer cell lines (sensitive: PEO1 and resistant: PEO1TaxR, PEO1CarbR) and/or in the ovarian tissue
biopsies (control – : SOV-1 and cancer: SOV-2/3/4/5). Proteins shown (n=189) were identified by liquid chromatography-tandem mass spectrometry
after in-gel trypsin digestion of the selected protein spots. Criteria used for protein hit selection were Min Peptide – 95 %, Min # Peptides – 2, Min
Protein – 99 % (Scaffold 3 Software, version 3.6.4). SSP, Sample spot protein number; MW, molecular weight; pI, isoelectric point; N/A, not
applicable; R, resistant; S, sensitive; P, partially resistant/sensitive.
Protein name                                                                           Accession        MW    pI                                         % Coverage
                                                                                                   number          (kDa)
                                                                                                                                                    Ovarian tissue biopsies         Ovarian cancer cell lines
                                                                                                                                        
                                                                                                                                               N/A        R          S           P           P           S          R          R
                                                                                                                                             SOV-1  SOV-2  SOV-3  SOV-4  SOV-5  PEO1  PEO1   PEO1
                                                                                                                                                                                                                           TaxR   CarbR
14-3-3 protein beta/alpha                                                1433B_HUMAN       28     4.76                                                                                 17%         
14-3-3 protein theta                                                         1433T_HUMAN       28     4.68                                                                   4.90% 7.30%        
14-3-3 protein zeta/delta                                                 1433Z_HUMAN       28     4.73                                                                   4.90%   17%         
26S protease regulatory subunit 4                                  PRS4_HUMAN        49     5.87                                                                   5.00% 2.70%    13%
60 kDa heat shock protein, mitochondrial                     CH60_HUMAN        61     5.24                            9.90%   8.20%    16%                2.10%    36%
60S acidic ribosomal protein P0                                    RLA0_HUMAN       34      5.7                                                                      23%     17%         
78 kDa glucose-regulated protein                                  GRP78_HUMAN     72     5.01                                                                                             28%
Abhydrolase domain-containing                                    ABHDA_HUMAN   34     6.29                                                                   8.50%                   
protein 10, mitochondrial
Actin, cytoplasmic 1                                                       ACTB_HUMAN       42     5.29                            5.60%                              14%     15%     16%
Adenosylhomocysteinase                                                SAHH_HUMAN      48     5.92                                                                   2.50%              6.20%
Adenylosuccinatesynthetaseisozyme 2                          PURA2_HUMAN     50     6.13                                                                   4.80%                   
Adenylyl cyclase-associated protein 1                           CAP1_HUMAN       52     8.26                                                                                             26%
ADP-sugar pyrophosphatase                                          NUDT5_HUMAN    24     4.87                                                                     12%                     
A-kinase anchor protein 12                                            AKA12_HUMAN   191    4.37                                                                   1.50%                   
Alcohol dehydrogenase 1B                                             ADH1B_HUMAN    40     8.63                                                      6.10%                                
Aldehyde dehydrogenase family 1 member A3            AL1A3_HUMAN     56     7.12                                                                                             21%
Aldehyde dehydrogenase X, mitochondrial                   AL1B1_HUMAN     57     5.96                                                                                             14%
Alpha-1-antichymotrypsin                                              AACT_HUMAN      48     5.32   4.50%                                                                                    
Alpha-actinin-4                                                               ACTN4_HUMAN   105    5.27                                                                                            5.70%
Alpha-enolase                                                                  ENOA_HUMAN      47     6.99                            6.20%   6.50%   9.20%  6.50%   35%     57%
Annexin A1                                                                     ANXA1_HUMAN    39     6.64                            3.20%   7.80%                 29%     29%     44%
Annexin A11                                                                   ANX11_HUMAN     54     7.53                                                                                            5.00%
Annexin A2                                                                     ANXA2_HUMAN    39     7.56    17%     10%     17%      18%      42%                6.20%    39%
Annexin A3                                                                     ANXA3_HUMAN    36     5.63                                                                                 28%         
Annexin A5                                                                     ANXA5_HUMAN    36     4.93                                                                     14%   2.80%        
Apolipoprotein A-I                                                          APOA1_HUMAN    31     5.27                                                      9.40%                           8.60%
Aspartate aminotransferase, mitochondrial                   AATM_HUMAN      48     8.98                                                                   6.70%                   
ATP synthase subunit alpha, mitochondrial                   ATPA_HUMAN        60     8.28                                                                                             29%
Bifunctional purine biosynthesis protein PURH           PUR9_HUMAN       65     6.27                                                                                            9.00%
C-1-tetrahydrofolate synthase, cytoplasmic                  C1TC_HUMAN      102    6.89                                                                                            2.10%
Calreticulin                                                                      CALR_HUMAN       48     4.29                                                                     13%     18%     21%
Calumenin                                                                       CALU_HUMAN      37     4.46                                                                     23%     13%         
Caprin-1                                                                           CAPR1_HUMAN     78     5.14                                                                                            9.30%
Cathepsin D                                                                     CATD_HUMAN       45      5.6                                                                    4.60% 2.20%        
Chloride intracellular channel protein 4                        CLIC4_HUMAN      29     5.45                                                                     13%   6.30%        
Cofilin-1                                                                          COF1_HUMAN       19     8.26                                                                     26%     18%     36%
Coiled-coil-helix-coiled-coil-helix                                CHCH3_HUMAN    26      8.5                                                                                8.40%        
domain-containing protein 3, mitochondrial
Complement component 1 Q subcomponent-               C1QBP_HUMAN     31     4.32                                                                   5.00% 5.00%        
binding protein, mitochondrial
Cytosol aminopeptidase                                                  AMPL_HUMAN      56     8.03                                                                                             27%
D-3-phosphoglycerate dehydrogenase                           SERA_HUMAN       57     6.31                                                                                             12%
Delta(3,5)-Delta(2,4)-dienoyl-CoA                               ECH1_HUMAN       36     5.99                                                                               7.60%        
isomerase, mitochondrial
Desmoplakin                                                                    DESP_HUMAN      250    6.44                                                                   0.80%                   
Dihydrolipoyllysine-residue succinyltransferase          ODO2_HUMAN       49      5.9                                                                    6.80% 3.10%  7.30%
component of 2-oxoglutarate dehydrogenase 
complex, mitochondrial
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Table III. Continued
Protein name                                                                    Accession               MW    pI            % Coverage
                                                                                         number                    (kDa)
                                                                                                                                                   Ovarian tissue biopsies Ovarian cancer cell lines
                                                                                                                                        
                                                                                                                                               N/A        R          S           P           P           S          R          R
                                                                                                                                             SOV-1  SOV-2  SOV-3  SOV-4  SOV-5  PEO1  PEO1   PEO1
                                                                                                                                                                                                                           TaxR   CarbR
DnaJ homolog subfamily C member 9                          DNJC9_HUMAN     30     5.58                                                                                 13%         
EF-hand domain-containing protein D2                        EFHD2_HUMAN     27     5.15                                                                     22%                     
Elongation factor 1-alpha 1                                            EF1A1_HUMAN      50      9.1                2.40%  5.00%   5.00%    12%    5.80%              8.40%
Elongation factor 1-delta                                                EF1D_HUMAN        31      4.9                                                                    8.50%                12%
Elongation factor 1-gamma                                            EF1G_HUMAN        50     6.27                                                                   7.60%                   
Elongation factor Tu, mitochondrial                              EFTU_HUMAN       50     6.31                            2.70%   5.80%   2.70%                20%     24%
Endoplasmin                                                                    ENPL_HUMAN       92     4.73                                                                                            4.40%
Enoyl-CoA hydratase, mitochondrial                             ECHM_HUMAN      31     5.88                                                                                 15%         
Eukaryotic initiation factor 4A-I                                    IF4A1_HUMAN       46     5.32                                                                   2.50%                11%
Eukaryotic translation initiation factor 5A-1                 IF5A1_HUMAN       17     5.08                                                                     26%                     
F-actin-capping protein subunit beta                             CAPZB_HUMAN    31     5.36                                                                                 14%         
Far upstream element-binding protein 1                        FUBP1_HUMAN     68     7.33                                                                                             20%
Fatty acid-binding protein, epidermal                            FABP5_HUMAN     15     6.82    26%                                                        6.70%   24%         
Fructose-bisphosphatealdolase A                                   ALDOA_HUMAN   39     8.39                            6.90%   6.90%    19%    3.80%                36%
Fumaratehydratase, mitochondrial                                 FUMH_HUMAN      55     6.99                                                                                              11%
Galectin-1                                                                        LEG1_HUMAN       15      5.3                                                                    5.90%   21%         
Galectin-7                                                                        LEG7_HUMAN       15     7.02    12%                                                         10%     22%         
GIPCPDZ domain containing family, member 1          GIPC1_HUMAN      36      5.9                                                                      11%                     
Glucosidase 2 subunit beta                                             GLU2B_HUMAN    59     4.33                                                                     18%                     
Glutathione S-transferase omega-1                                GSTO1_HUMAN     28     6.23                                                                     17%     14%         
Glutathione S-transferase P                                            GSTP1_HUMAN     23     5.44                                                      9.00%    15%     15%         
Glyceraldehyde-3-phosphate dehydrogenase                G3P_HUMAN          36     8.58   8.70%    14%     13%      14%      27%    8.70% 8.70%    50%
G-rich sequence factor 1                                                 GRSF1_HUMAN     53     5.11                                                                               4.00%        
GTP-binding nuclear protein Ran                                  RAN_HUMAN         24      7.2                                                                      10%   6.00%        
Guanine nucleotide-binding                                           GBLP_HUMAN       35      7.6                                                                    8.50%   35%         
protein subunit beta-2-like 1
Heat shock 70 kDa protein 1A/1B                                 HSP71_HUMAN      70     5.48                                                                                             14%
Heat shock cognate 71 kDa protein                               HSP7C_HUMAN     71     5.37                                                                                             39%
Heat shock protein beta-1                                               HSPB1_HUMAN     23     5.98                                                                               8.80%        
Hemoglobin subunit beta                                                HBB_HUMAN         16     6.81    67%     46%    8.80%   8.80%    51%     28%                     
Heterogeneous nuclear ribonucleoprotein D0               HNRPD_HUMAN    38     7.61                                                                   2.80%              6.80%
Heterogeneous nuclear ribonucleoprotein F                  HNRPF_HUMAN    46     5.37                                                                                            6.50%
Heterogeneous nuclear ribonucleoprotein H                 HNRH1_HUMAN    49     5.89                                                                     28%     13%    6.00%
Heterogeneous nuclear ribonucleoprotein H3               HNRH3_HUMAN    38     6.37                                                                   8.40% 2.60%  3.50%
Heterogeneous nuclear ribonucleoprotein K                 HNRPK_HUMAN    51     5.39                                         2.60%                8.90%   13%     37%
Heterogeneous nuclear ribonucleoprotein L                  HNRPL_HUMAN    64     8.46                                                                                             15%
Heterogeneous nuclear ribonucleoprotein Q                 HNRPQ_HUMAN    70     8.68                                                                     11%                     
Heterogeneous nuclear ribonucleoproteins A2/B1        ROA2_HUMAN       37     8.97                                         7.40%                9.90%                22%
Heterogeneous nuclear ribonucleoproteins C1/C2        HNRPC_HUMAN    34     4.95                                                                     13%   2.90%    10%
High mobility group nucleosome-binding                    HMGN5_HUMAN   32      4.5                                                                    3.50% 1.60%  4.10%
domain-containing protein 5
Histidine-tRNA ligase, cytoplasmic                               SYHC_HUMAN       57     5.73                                                                     14%   7.10%    19%
Histone H2B type 1-M                                                   H2B1M_HUMAN    14    10.32                                                                                           6.70%
Hypoxanthine-guanine phosphoribosyltransferase        HPRT_HUMAN       25     6.24                                                                     12%     17%         
Ig gamma-1 chain C region                                            IGHG1_HUMAN     36     8.46   8.80%                                                                    13%         
Inosine-5'-monophosphate dehydrogenase 2                 IMDH2_HUMAN     56     6.46                                                                                            7.80%
Isoform 2 of Shootin-1                                                   A0MZ66-2|               53     5.27                                                                                            4.60%
                                                                                         SHOT1_HUMAN
Lactoylglutathionelyase                                                  LGUL_HUMAN       21     5.12                                                                     14%     16%         
Lamin-B1                                                                         LMNB1_HUMAN    66     5.11                                                                                            7.80%
Leukocyte elastase inhibitor                                           ILEU_HUMAN        43      5.9                                                                                  10%         
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Protein name                                                                    Accession               MW    pI            % Coverage
                                                                                         number                    (kDa)
                                                                                                                                                   Ovarian tissue biopsies Ovarian cancer cell lines
                                                                                                                                        
                                                                                                                                               N/A        R          S           P           P           S          R          R
                                                                                                                                             SOV-1  SOV-2  SOV-3  SOV-4  SOV-5  PEO1  PEO1   PEO1
                                                                                                                                                                                                                           TaxR   CarbR
LIM and SH3 domain protein 1                                     LASP1_HUMAN     30     6.61                                                                                            8.80%
L-lactate dehydrogenase A chain                                   LDHA_HUMAN      37     8.46                                                                                             30%
L-lactate dehydrogenase B chain                                   LDHB_HUMAN      37     5.72                                                                     15%     43%     20%
Macrophage-capping protein                                          CAPG_HUMAN       38     5.82                                                                     14%   8.00%  3.70%
Malate dehydrogenase, cytoplasmic                              MDHC_HUMAN     36     6.89                                                                               8.70%        
Malate dehydrogenase, mitochondrial                           MDHM_HUMAN    36     8.54                              13%                   16%    5.60%                19%
Microtubule-associated protein 4                                   MAP4_HUMAN      121    5.32                                                                   3.40%                   
Microtubule-associated protein                                     MARE1_HUMAN    30     5.02                                                                     10%                     
RP/EB family member 1
Myosin light polypeptide 6                                            MYL6_HUMAN      17     4.56                                                                     21%     22%         
Myristoylated alanine-rich C-kinase substrate              MARCS_HUMAN   32     4.46                                                                     19%                     
Nascent polypeptide-associated                                     NACA_HUMAN      23     4.52                                                                     13%     26%         
complex subunit alpha
Neutral alpha-glucosidase AB                                        GANAB_HUMAN  107    5.58                                                                                            3.50%
Nitrilase homolog 1                                                        NIT1_HUMAN         36     7.91                                                                               6.40%        
Nuclear autoantigenic sperm protein                             NASP_HUMAN       85     4.26                                                                                            2.30%
Nucleolin                                                                         NUCL_HUMAN      77      4.6                                                                                1.30%  5.90%
Nucleophosmin                                                                NPM_HUMAN         33     4.64                                                                               3.10%    29%
Nucleoporin p54                                                              NUP54_HUMAN     55     6.53                                                                                            5.70%
Nucleoside diphosphate kinase A                                  NDKA_HUMAN      17     5.82                                                                                 47%         
Nucleosome assembly protein 1-like 1                          NP1L1_HUMAN      45     4.34                                                                   5.60% 2.60%  5.40%
Paraspeckle component 1                                               PSPC1_HUMAN      59     6.26                                                                                            7.50%
PDZ and LIM domain protein 1                                     PDLI1_HUMAN      36     6.55                                                                                             39%
Peptidyl-prolyl cis-trans isomerase A                            PPIA_HUMAN         18     7.68                                                                     33%     28%     45%
Peptidyl-prolyl cis-trans isomerase FKBP4                  FKBP4_HUMAN     52     5.35                                                                                 17%         
Peroxiredoxin-1                                                               PRDX1_HUMAN     22     8.27                                                      5.50%    11%     18%     22%
Peroxiredoxin-2                                                               PRDX2_HUMAN     22     5.67               9.10%               9.10%   9.10%    19%     19%     15%
Peroxiredoxin-5, mitochondrial                                      PRDX5_HUMAN     22     6.73                                                                               8.90%        
Peroxiredoxin-6                                                               PRDX6_HUMAN     25     6.02                                                                   8.50%   31%         
Phosphoglycerate kinase 1                                             PGK1_HUMAN       45      8.3                               12%    3.60%    20%     12%                 34%
Phosphoglyceratemutase 1                                              PGAM1_HUMAN    29     6.75                                                                     27%   7.10%    13%
Platelet-activating factor acetylhydrolaseIB                 PA1B3_HUMAN      26     6.33                                                                   7.80% 7.40%        
subunit gamma
Poly(rC)-binding protein 1                                             PCBP1_HUMAN     37     6.66                                                                               3.10%    11%
Poly(rC)-binding protein 2                                             PCBP2_HUMAN     39     6.33                                                                               9.90%        
Polymerase I and transcript release factor                     PTRF_HUMAN        43      5.5                                                                                6.70%        
Prelamin-A/C                                                                  LMNA_HUMAN     74     6.57                                                                                             16%
Profilin-1                                                                         PROF1_HUMAN     15     8.47                                                                     20%     53%         
Prohibitin                                                                         PHB_HUMAN         30     5.57                                                                     34%     11%         
Prohibitin-2                                                                      PHB2_HUMAN       33     9.83                                                                   7.70%                   
Proliferating cell nuclear antigen                                   PCNA_HUMAN       29     4.57                                                                                 29%     12%
Proliferation-associated protein 2G4                             PA2G4_HUMAN      44     6.12                                                                   8.40%              3.00%
Proteasome subunit alpha type-1                                   PSA1_HUMAN        30     6.15                                                                                 16%         
Proteasome subunit alpha type-3                                   PSA3_HUMAN        28     5.19                                                                   7.50% 4.70%        
Proteasome subunit alpha type-6                                   PSA6_HUMAN        27     6.34                                                                     14%     12%         
Proteasome subunit alpha type-7                                   PSA7_HUMAN        28      8.6                                                                                  27%         
Proteasome subunit beta type-3                                     PSB3_HUMAN        23     6.12                                                                   7.80% 4.40%        
Proteasome subunit beta type-6                                     PSB6_HUMAN        25     4.91                                                                                 13%         
Proteasome subunit beta type-7                                     PSB7_HUMAN        30     5.61                                                                   7.90% 7.20%        
Protein disulfide-isomerase                                            PDIA1_HUMAN      57     4.69                                                                                             29%
Protein disulfide-isomerase A3                                      PDIA3_HUMAN      57     5.61                            2.20%                6.90%    14%     21%     29%
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Protein name                                                                    Accession               MW    pI            % Coverage
                                                                                         number                    (kDa)
                                                                                                                                                   Ovarian tissue biopsies Ovarian cancer cell lines
                                                                                                                                        
                                                                                                                                               N/A        R          S           P           P           S          R          R
                                                                                                                                             SOV-1  SOV-2  SOV-3  SOV-4  SOV-5  PEO1  PEO1   PEO1
                                                                                                                                                                                                                           TaxR   CarbR
Protein DJ-1                                                                    PARK7_HUMAN     20     6.32                                                                   9.00%   16%         
Protein S100-A7                                                              S10A7_HUMAN      11     6.26    38%                               20%      11%      11%     11%         
Protein S100-A8                                                              S10A8_HUMAN      11      6.5     12%                                                         25%     31%     12%
Protein S100-A9                                                              S10A9_HUMAN      13     5.71    13%                               25%                   45%     31%     28%
Protein SET                                                                     SET_HUMAN          33     4.22                                                                   7.20% 3.80%        
Purine nucleoside phosphorylase                                   PNPH_HUMAN       32     6.45                                                                               9.70%        
Pyruvate kinase isozymes M1/M2                                 KPYM_HUMAN      58     7.95                                                                                             54%
Ran-specific GTPase-activating protein                        RANG_HUMAN      23     5.19                                                                     11%   5.50%        
Rho GDP-dissociation inhibitor 1                                  GDIR1_HUMAN     23     5.01                                                                     22%     18%         
Serine hydroxymethyltransferase, mitochondrial          GLYM_HUMAN      56     8.11                                                                                              20%
Serine protease HTRA2, mitochondrial                         HTRA2_HUMAN    49     6.12                                                                   9.80%                   
Serine/arginine-rich splicing factor 1                             SRSF1_HUMAN      28    10.37                                                                  9.30% 4.80%        
Serpin B3                                                                         SPB3_HUMAN        45     6.35   6.90%                                                      9.50% 5.10%        
Serpin B4                                                                         SPB4_HUMAN        45     5.86   6.90%                                                      6.90% 9.70%        
Serpin B5                                                                         SPB5_HUMAN        42     5.72                                                                   2.40% 5.60%        
Serum albumin                                                                ALBU_HUMAN      69     5.67   2.50%  2.30%  2.30%   5.90%   2.50%  4.90% 7.40%  9.00%
Serum deprivation-response protein                              SDPR_HUMAN       47     5.14                                                                                            7.10%
Single-stranded DNA-binding                                       SSBP_HUMAN        17     8.24                                                                     16%                     
protein, mitochondrial
Stress-70 protein, mitochondrial                                    GRP75_HUMAN     74     5.44                                         3.70%                                          18%
Stress-induced-phosphoprotein 1                                   STIP1_HUMAN       63      6.4                                                                                              18%
Superoxide dismutase [Mn], mitochondrial                   SODM_HUMAN      25     6.86                                                        17%     10%                     
T-complex protein 1 subunit beta                                   TCPB_HUMAN       57     6.02                                                                                            5.80%
T-complex protein 1 subunit eta                                     TCPH_HUMAN       59     7.55                                                                                             16%
T-complex protein 1 subunit theta                                 TCPQ_HUMAN       60     5.41                                                                               1.80%  5.80%
Thioredoxin                                                                     THIO_HUMAN        12     4.82                                                                     12%     21%         
Thymidylate kinase                                                         KTHY_HUMAN      24     8.43                                                                                 14%    5.20%
Transgelin-2                                                                     TAGL2_HUMAN     22     8.45                                                                   6.00%                31%
Transitional endoplasmic reticulum ATPase                  TERA_HUMAN       89     5.14                                                                                             28%
Translationally-controlled tumor protein                       TCTP_HUMAN       20     4.84                                                                                 22%         
Trifunctional enzyme subunit beta, mitochondrial        ECHB_HUMAN       51     9.24                                         2.70%   6.10%                                
Triosephosphate isomerase                                             TPIS_HUMAN         31     5.65                              10%      23%      29%     40%     51%     53%
tRNA-splicing ligase RtcB homolog                             RTCB_HUMAN       55     6.77                                                                                            5.00%
Tropomyosin alpha-1 chain                                            TPM1_HUMAN       33     4.69                                                                               3.50%    19%
Tropomyosin alpha-3 chain                                            TPM3_HUMAN       33     4.68                                                                                 12%         
Tryptophan-tRNA ligase, cytoplasmic                           SYWC_HUMAN      53     5.83                                                                                            5.70%
Tubulin alpha-1A chain                                                  TBA1A_HUMAN    50     4.94                                                                   7.30%   25%     14%
Tubulin alpha-1B chain                                                  TBA1B_HUMAN     50     4.94                                                                                 31%     20%
Tubulin alpha-4A chain                                                  TBA4A_HUMAN    50     4.93                                                                                 29%     20%
Tubulin beta chain                                                           TBB5_HUMAN       50     4.78                                                                   4.30%   30%     17%
Tubulin beta-6 chain                                                       TBB6_HUMAN       50     4.77                                                                                 15%         
Ubiquitin-conjugating enzyme E2 K                             UBE2K_HUMAN    22     5.33                                                                     24%   5.00%        
Ubiquitin-conjugating enzyme E2 variant 2                  UB2V2_HUMAN     16     8.05                                                                   6.90%   13%    6.90%
UDP-glucose 6-dehydrogenase                                      UGDH_HUMAN      55     6.73                                                                                            4.00%
UMP-CMP kinase                                                           KCY_HUMAN         22     5.44                                                                     11%   6.60%        
Uroporphyrinogen decarboxylase                                  DCUP_HUMAN       41     5.77                                                                     12%                     
UV excision repair protein RAD23 homolog B            RD23B_HUMAN     43     4.77                                                                   2.20% 2.20%    20%
Vimentin                                                                          VIME_HUMAN       54     5.05                                                                   2.40%   15%    5.20%
Voltage-dependent anion-selective channel protein 1   VDAC1_HUMAN    31     8.63                                           11%    4.20%                                
Voltage-dependent anion-selective channel protein 2   VDAC2_HUMAN    32     7.66                                                                     12%     22%         
Xaa-Pro dipeptidase                                                        PEPD_HUMAN       55     5.64                                                                   1.80% 7.10%  7.10%
Discussion
2D-GE proteomics. One of the advantages of using 2D-GE is
that the proteins and their charged isoforms can be compared
directly. The spot selection process using PDQuest Advanced
software is illustrated using representative examples (Figure
3). The histograms allow for rapid comparison of spot
intensity among gels. They are also useful as tools for
detecting problems such as mismatched spots and spots
whose quantification is suspiciously far from average.
Restricted criteria for protein identification. Depending on
instruments used, different criteria are used in MASCOT
searches. In this project, we used restricted criteria in order to
increase the confidence of identification instead of breadth of
identification. Two online search engines, MASCOT (Matrix
Science) (28) and X!Tandem (The GPM) (29) were used. In
order to minimize the chances of false-positive identification
of contaminant proteins, protein hits were accepted if the
MASCOT protein score exceeded 100 and at least one of the
theoretical MW and pI values matched the experimental value.
Experimental MW and pI were estimated based on relative
positions to MW markers and corresponding vertical
alignment to pH values on 2D gels; or, 20 <MASCOT protein
score <100 and theoretical MW and pI values were both
similar to the experimental values; or, 20 <MASCOT protein
score <100 and at least one of the theoretical MW and pI
values was similar to the experimental values and first hits in
the MASCOT search result corresponded to the same first hits
in the X!Tandem search results or the protein identified
belonged to the same family (isoforms). Keratin and trypsin
were removed from the hit list of each spot (30). Searches and
analysis were performed using Scaffold 3 (Proteome
Software), and the criteria used for protein hit selection was:
Min Peptide – 95%, Min # Peptides – 2, Min Protein – 99%
and 1% false discovery rate (31, 32). This search method
resulted in a list of 189 proteins reliably identified. Among
these 189 proteins, 20 were expressed in sensitive PEO1 cells,
79 in the drug-resistant variants and 90 were common to all
cell lines (See Supplementary data).
Western blot. Overall, western blot results confirmed the
results obtained by MS and 2D-GE spot intensity
measurements in terms of the presence and expression of the
selected proteins. 
In the western blot results, PGAM1 appeared to be up-
regulated in both drug-resistant ovarian cancer cell lines,
confirming the previous MS/spot intensity results. The blot
probed with anti-UBE2K presented two sets of bands (Table
IV) and agreed with proteomics study that indicated an
absence of this protein from PEO1CarbR cells. The antibody
to 14-3-3 used was able to recognise all 14-3-3 protein
isoforms, 14-3-3β, 14-3-3T and 14-3-3ζ , and thus, the
western blotting results fit with the MS result well. Finally,
the presence and fold regulation of THIO was also confirmed
by the western blot results.
Quantification and pathway analysis. As shown above,
occasionally the same protein can be identified in multiple spots
due to post-translational modifications (see Supplementary
data). In order to avoid errors in the interpretation of spot
intensity data, which would influence the analysis of differences
in protein expression between distinct samples, spot intensity
was studied using two alternative approaches. Firstly, ‘consider
the spot position’: only spots located in equivalent positions on
different gels in which a certain protein was identified were
used for quantitative purposes. In principle, spots located in the
same place on different gels, when comparing similar proteomic
samples, may correspond to the same protein and are given the
same SSP number. In this case, only spots with the same SSP
number were compared between samples.
Secondly, "ignoring the spot position" on the gel: all spots
on one gel in which a certain protein was identified were
considered for quantification purposes. In this case, the total
presence of a protein in a gel or sample was considered as a
sum of the intensities of all the spots in which this protein
was identified. The total intensity values were then compared
between samples. 
It is noteworthy that 4 out of 63 sensitive exclusive
protein differences in PEO1CarbR and two out of 33 in
PEO1TaxR; while three out of 58 and three out of 40 in
resistant exclusive proteins, respectively (See Supplementary
data). We decided to use the data "ignore spot position" for
pathway analysis, although both data sets generate the same
top 10 pathway hits (See Supplementary data).
However, the expression of most proteins was different; the
number of up-regulated, down-regulated and unchanged proteins
in each canonical pathway was distinct between the two datasets
(see Supplementary data). Figure 1 shows the pathways
identified in PEO1TaxR (Figure 1 top) and PEO1CarbR (Figure
1 bottom) cell lines. In general, the pathways that differ are very
similar in these two cell lines but the nature of those changes
differs. The Warburg effect (which includes glycolysis,
gluconeogenesis and trichloroacetic acid cycle) was found to be
up-regulated in both resistant cell lines, as reported before (33).
It is interesting to note that there were significant changes in
nucleotide and amino acid metabolic pathways (Figure 1), in
which PEO1TaxR showed the most down-regulation and
PEO1CarbR showed some to be up-regulated. It emerged that
phosphoinositide 3-kinase/ protein kinase B (PI3K/AKT),
extracellular signal-regulated kinases (ERK), hypoxia-inducible
factor 1-alpha (HIFα), endoplasmic reticulum stress, endothelin-
1 (ET1), α-adrenergic signalling (ADRα) and NRF2 etc. were
the key pathways changed for these two drug-resistant cell lines:
PEO1TaxR showed relative up-regulation, whilst PEO1CarbR
showed down-regulation of these. 
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Targeting the proteasome. As part of the validation process
of the proteomics study in the PEO1 cell line panel, we
examined more closely a pathway that had been highlighted
as dysregulated in drug-resistant versus drug-sensitive cells.
There is considerable evidence to suggest that targeting the
proteasome is an effective approach to killing tumour cells
whilst sparing healthy cells. This can be attributed to the up-
regulation of proteasomal activity by intracellular oncogenic
factors in tumour tissues, which not only means that cancer
cells are more dependent on proteasomes than healthy cells,
but also that they can be more easily targeted. Proteasomes
are involved in the degradation of tumour-suppressor
proteins, hence the increased proteasome activity in tumour
cells results in more degradation of suppressors, thus leading
to cancer cell survival and proliferation (34).
Whilst there are several classes of proteasome inhibitors
that target various different points in the ubiquitin-
proteasomal-pathway, bortezomib, a reversible peptide
boronic acid inhibitor, which inhibits proteasomal
chymotrypsin-like activity by forming a complex between
the N-terminal threonine and the boronic acid pharmacore,
has been investigated extensively (35, 36). Bortezomib was
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Figure 1. Pathway analysis result in of PEO1TaxR (top) and PEO1CarbR (bottom) cell lines. Red: Up-regulated proteins; Green: down-regulated
proteins.
developed for clinical trials based on its potency against a
potentially wide range of human cancer types, and has been
shown to be very effective against multiple myeloma and
non-Hodgkin lymphoma.
A previous report detailed the effects of bortezomib
against human ovarian cancer cell lines, with IC50 values
ranging between 1.5 and 30 nM (37). Considering the
paclitaxel-resistant cell line PEO1TaxR in the present study,
we found a relatively high IC50 value forbortezomib (Table
II). There is evidence that this could be, in part, due to the
high levels of expression of P-gp present in PEO1TaxR cells.
This is based on a recent study which indicated that
bortezomib is a substrate for P-gp activity (38). In 2008, a
clinical trial was carried out on patients with taxane and
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Figure 2. Flow cytometric data obtained using the annexinV fluorescein isothiocyanate method in combination with propidium iodide (PI). PEO1,
PEO1CarboR and PEO1TaxR cells were treated with bortezomib (50 nM) and carboplatin (5 μM) (A) or paclitaxel (B) at 6 nM, either singly or in
combination for 48 h and then harvested for flow cytometric analysis. Numbers shown indicate the remaining live cell population (bottom left hand
quadrant), shown as a percentage with the standard deviation shown in parentheses. All experiments were performed in triplicate, with the cytograms
of a typical data set shown.
platinum-refractory EOC using a combination of carboplatin
plus increasing concentrations of bortezomib. The results
from this trial suggested an optimum dose of bortezomib
recommended for administration in combination with
carboplatin which was associated with disease stabilisation
in some patients (39).
Al-Eisawi et al. showed that bortezomib prevented the
degradation of the copper transporter 1, essential for cellular
uptake of platinum (40). This effect was associated with
enhanced accumulation of platinum, DNA adduct formation
and oxidative stress in a panel of drug-resistant ovarian
cancer cell lines, lending support to our findings. Recently,
Steg et al. (37) showed that proteasome inhibition reduced
expression of hedgehog target genes [protein patched
homolog 1 (PTCH1), zinc finger protein (GLI1 and GLI2] in
ovarian cancer cells. The authors also showed that
bortezomib treatment increased paclitaxel sensitivity through
apoptosis and G2M blockade. Expression of the multidrug-
resistance gene ATP-binding cassette sub-family B member
1 (ABCB1) decreased, whilst the acetylation of α-tubulin, a
marker of microtubule stabilization, increased following
bortezomib treatment (38). These results suggest that
proteasome inhibition, through a combination of altered
microtubule dynamics and hedgehog signaling, may
circumvent taxane resistance. Like many targeted therapies,
bortezomib has reported ‘off-target’ effects. The eukaryotic
initiation factor 4A-1 (EIF4E1) has been shown to be
targeted by bortezomib in haematological malignancies,
giving rise to G2M blockade (41). Table III from our
proteomics study indicates that PEO1CarbR cells expressed
the highest level of this protein, which may go some way to
explaining the preferential sensitisation effect we saw in this
cell line (Figure 2). Moreover, the same study demonstrated
synergy between chemotherapy and bortezomib, lending
support to our findings (41).
The data obtained in the present study support the use of
bortezomib in combination with chemotherapy for the
management of heavily pretreated EOC.
Protein expression patterns in clinical samples of ovarian
tissues. Proteins indicated in bold in Table V have been
confirmed for the first time in both cell lines and biopsy
samples. The agreement in the proteomics readout in both
cell lines and human tumour biopsies supports the use of cell
line models as a realistic discovery platform that extrapolates
to the clinical scenario. The data obtained in this part of the
study have increased our knowledge of molecular
mechanisms of development of chemoresistance in ovarian
cancer, in spite of the technical difficulties encountered in
the approaches used.
Many of the proteins identified from patients with drug-
resistant EOC were up-regulated (Table V). Some of them [60
kDa heat-shock protein (CH60), ENOA, cathepsin D (CATD),
EFTU, G3P and GRP75] were confirmed by a quantitative
proteomic analysis using an iTRAQ approach (42).
Interestingly, APOA1 and PRDX2 have also been found lobe
up-regulated in ovarian cyst fluid of patients diagnosed with
advanced serous ovarian adenocarcinoma (43). Additionally,
studies conducted in Taxol- and platinum-resistant ovarian
cancer cell lines have reported CH60, ENOA, ANXA2,
CATD, heterogeneous nuclear ribonucleoprotein K (HNRPK)
and heterogeneous nuclear ribonucleoproteins A2/B1 (ROA2)
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Figure 3. Examples of 2D-gel and spot selection using PDQuest Advanced 8.0.1. Yellow squares indicate proteins of interest. Histogram at upper
left shows the relative quantity for the corresponding spot in each of the different gels, SOV-2/3/4/5/1 (bars from left to right). 
to be up-regulated in resistant cells when compared to their
sensitive counterparts (24, 25, 44). Annexins A1 and A2 have
been described as major substrates for the tyrosine
phosphorylation carried out by the epidermal growth factor
receptor (EGFR) (45). Moreover, we previously published the
finding of up-regulation of EGFR in our drug-resistant PEO1
cell lines (19), which lends further support to our findings. The
role of annexins in cancer development is somewhat
controversial but annexin A1 is associated with a drive in
cellular proliferation and has been reported to be strongly up-
regulated in a number of cancer cell lines (46). These studies
further support the claim that some of the dysregulated
proteins identified in the clinical samples (SOV-2, SOV-4,
SOV-5) could be potential markers of drug resistance.
Candidate biomarkers of drug-resistant ovarian cancer.
Taking advantage of the availability of a non-cancerous
(control) tissue sample amongst the biopsies analyzed in this
study, we were able to then compare the proteomics readout
of cancer versus non-cancer tissues, albeit it to a limited
extent. In our analysis, only those proteins that were
similarly different in expression for the four ovarian cancer
tissues were considered potential biomarkers of disease
status e.g. treatment response.
Nine proteins in total were found to be similarly increased
in expression amongst the cancerous biopsies versus non-
cancerous tissue. Out of these nine proteins, expression of
alpha-1-antichymotrypsin (AACT), fatty acid-binding protein,
epidermal (FABP5), galectin-7 (LEG7), haemoglobin subunit
beta (HBB), Ig gamma-1 chain C region (IGHG1) and serpin
B3 (SPB3) were reduced, whilst EF1A1 and G3P, were
increased in expression. In support of our findings, Wang and
co-workers reported EF1A1 and G3P to be up-regulated in a
quantitative proteome analysis of ovarian cancer tissues,
while HBB was down-regulated (42).
Other studies have been carried out with the aim of
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Table IV. Results of target validation through western blotting (WB) assay. Ovarian cancer cell line proteins (20 μg per well from PEO1, PEO1TaxR
and PEO1CarbR) were separated by SDS-PAGE using precast gels and transferred onto nitrocellulose membranes. Membranes were blocked, probed
with primary and secondary antibodies and developed using a chemiluminescent substrate. 
The experiment was carried out at least twice for each antibody. +, Presence; ++, up-regulation; −, absence.
discovering novel biomarkers for the diagnosis of ovarian
cancer using serum. Several biomarkers have been
suggested, including haptoglobin and transferrin (47),
kallikrein 10 (48), osteopontin (49), apolipoprotein A1
(glycoprotein) (50), truncated form of transthyretin and
cleavage fragment of inter-α-trypsin inhibitor heavy chain
H4 (51). Those particular studies used large numbers of
clinical samples from patients with EOC and from normal
healthy individuals for discovery of biomarkers for disease
detection, in contrast to our current study, which considered
biomarkers of prognostic value (i.e. for use in disease
monitoring/management as opposed to diagnosis). 
In conclusion, we set-up a confident 2D-gel proteomics
method to correlate protein identification in ovarian cell lines
along with clinical biopsies. Proteins and pathways indicated
potential biomarkers of drug-resistant disease. Three ovarian
cancer lines were successfully analyzed allowing paclitaxel
and carboplatin resistance-associated proteins to be identified
by MS. Restricted criteria were applied in order to increase
confidence rather than the breadth of identification. The
expression differences of a total 189 identified proteins were
used in the IPA. This then informed our approach to using
combined treatment targeting proteasome pathway with
bortezomib to achieve a re-sensitisation of drug-resistant
ovarian cancer cells. In addition, five surgical biopsies of
ovarian tissues with a range of pathologies were also analyzed
and expressions compared to those identified in cell lines. The
identified proteins, CH60, ENOA, EFTU, G3P, GRP75,
APOA1, PRDX2 and ANXA, may potentially be biomarkers.
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